• Most Popular
  • Most Shared

UPDATE 2-Icahn says Lions Gate $6 offer fair

Mon Mar 29, 2010 5:55pm EDT

Stocks

   

* Icahn says Lions Gate bid fair, when asked would raise

Stocks  |  Mergers & Acquisitions  |  Bonds  |  Global Markets  |  Cyclical Consumer Goods

* Says only reason stock trading above $6 is him (Adds details, background, byline)

By Sue Zeidler

LOS ANGELES, March 29 (Reuters) - Billionaire investor Carl Icahn said on Monday his $6-a-share offer for Lions Gate Entertainment (LGF.N) is fair and that the only reason that the company's stock is trading above $6 is because of him.

The financier, citing the declining values of film libraries and what he perceives as mismanagement by Lions Gate in its moviemaking endeavors, defended the offer when asked by Reuters if he would raise his bid.

"Based on the fact that these film libraries are in decline and that management has done poorly with their big budget movies and the rumors the "Killers' might be a $75 million flop, I firmly believe that the stock would be lower than the $4.85 it sold at when we started to buy it again in early February," he said.

"The company's board of directors believes that Icahn's bid is inadequate and no amount of rhetoric is going to distract shareholders from that point," said Lions Gate spokesman Peter Wilkes on Monday in response to Icahn's statements.

In a statement last week in which it said Icahn had been trying to distract shareholders from a "woefully inadequate" bid, Lions Gate defended its track record and its theatrical business in particular.

"We have achieved profitability on approximately 70 percent of our film releases over the past ten years -- one of the highest success rates in the industry," Lions Gate said.

It said its upcoming slate which includes the Ashton Kutcher/Katherine Heigl film "Killers" as well as the newest film from the popular Tyler Perry franchise, reflects its focus on large niches where it has proven success.

Last week, sources familiar with the matter told Reuters that Lions Gate had decided it will not increase its offer for Metro-Goldwyn-Mayer, essentially withdrawing from the auction after Icahn offered to buy Lions Gate in a move designed to hinder the studio's bid for MGM. [ID:N2556843].

Analysts said Lions Gate's withdrawal or defeat in the MGM bidding might have boosted the stock as a potential acquisition of MGM was seen as weighing on the stock.

Growing perceptions that there will be a higher bid for Lions Gate, whether or not its from Icahn, are also boosting the stock.

"Icahn has set the wheels of motion for this company to be an acquisition candidate. I see $6 as a floor and the market expects there will be other offers or that ultimately this company will be bought," said Richard Dorfman, managing director for Richard Alan Inc, a media investment firm with a stake in Lions Gate.

(Editing by Bernard Orr)



 
 
Add a Comment

More from Reuters

Photo

Chrysler on track to break-even in 2010

NEW YORK (Reuters) - Chrysler Group LLC is on track to break even on an operating basis in 2010 and is ahead of its turnaround targets, Chief Executive Sergio Marchionne said on Tuesday.

 A woman cries at Lubyanka metro station in Moscow March 30, 2010. REUTERS/Alexander Natruskin

"Silent war" spills into Moscow

It began as a grassroots separatist movement, but the insurgency in the North Caucasus has mutated into a campaign for holy war against Russia.  Full Article 

Researchers work at the "Cloning & Genetic Engineering" section of the Beijing Genomics Institute in Shenzhen, southern China March 3, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. Picture taken March 3, 2010. REUTERS/Bobby Yip
Special Report:

Your DNA and the cancer fight

A gene test that may be only two years away could warn doctors that they missed something. It's just one tantalizing glimpse of what’s ahead as Reuters delves into the state of genomics.  Full Article | Video